SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease

Castration-resistant prostate cancer (CRPC) remains a lethal disease despite the introduction of second generation androgen receptor (AR) directed therapies. Resistance to AR directed therapies, such as abiraterone and enzalutamide, emerges through diverse alterations in the AR pathway or transition...

Descripción completa

Detalles Bibliográficos
Autores principales: Risbridger, Gail, Ashikari, Daisaku, Lawrence, Mitchell, Obinata, Daisuke, Wang, Hong, Sandhu, Shahneen, Azad, Arun, Taylor, Renea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551945/
http://dx.doi.org/10.1210/js.2019-SAT-330

Ejemplares similares

Ejemplares similares